TOKYO--(BUSINESS WIRE)--Sosei Group Corporation (“Sosei”)(TOKYO:4565) confirms that Novartis Pharma K.K. launched once-daily Ultibro ® Inhalation Capsules (“Ultibro ® ”; glycopyrronium / indacaterol), ...

The IGNITE programme comprises 11 studies. The first eight studies were completed in 2012. New analyses of the data revealed that patients suffering from chronic obstructive pulmonary disease (:COPD) ...

QVA149 (indacaterol/glycopyrronium) is the first once-daily fixed-dose combination of both a LABA and a LAMA bronchodilator to gain positive CHMP opinion Pivotal ...

TOKYO and LONDON, Nov. 28, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro® Breezhaler® (an inhaled once-daily ...

QUANTIFY study met primary endpoint demonstrating non-inferiority of Ultibro®Breezhaler® vs tiotropium 18 mcg plus formoterol 12 mcg in improving health-related quality of life outcomes[1],[2] ...

FLAME was a randomized, double-blind, double-dummy, parallel-group, non-inferiority, active-controlled 52-week study involving 3,362 COPD patients and conducted at 356 sites across 43 countries[6].

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. ULTIBRO BREEZHALER contains the active ingredients indacaterol and ...

Novartis has announced positive results from the FLASH study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD ...

The digital press release with multimedia content can be accessed here: Basel, May 21, 2014 - Novartis announced today new data from the QUANTIFY study, which ...